Biotech Values

[caravon]

jq1234 wrote:

That sounds rationalization to me unfortunately. Giving up US market is never a good strategy when EU HCV market will take significant time, and HCV market will become much more competitive a few years down the road.

I agree with every single word of this statement.

However, let us admit that ABBV cannot compete with GILD for the 8-week treated pts. ABBV just has no data to support this. At the same time, physicians will be very hesitant to use the Gild 8-week regiment for it relatively high failure rate.

I also assume that ABBV HCV management team did talk to major insurers before pricing their drug. I hope they were not stupid and stubborn like they were during their failed merger adventure to reduce their tax burden.

PS
I would like to see Vieira Pak somewhere around $75-78K. Nevertheless, the $10K price discount per patient is still lots of money.